Urate-Lowering Therapy May Reduce Type 2 Diabetes Risk in Patients With Gout
Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.
Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.
Researchers evaluated the adrenocorticotropic hormone as an alternative therapeutic option for acute gout, and its potential mechanisms of action.
Patients with gout receiving urate lowering therapy by a treat-to-target approach demonstrate a reduced burden of monosodium urate crystals detected on ultrasound.
From 1990 to 2017, the burden of gout increased across the world.
Researchers assessed whether initiating guideline-concordant gout therapy improved arterial function and reduced inflammation.
Researchers determined the association between gout and epilepsy and the risk for epilepsy in patients with gout.
Researchers performed a cost-effectiveness analysis for colchicine prophylaxis in preventing gout flares during allopurinol initiation.
Researchers investigated the association between gout and the risk for erectile dysfunction.
Colchicine could potentially play a role in the treatment of hospitalized patients with COVID-19.
The American College of Rheumatology developed guidelines for the management of gout, including use of urate-lowering therapy, flare treatment, and lifestyle and medication recommendations.